Recently several cases have been filed that challenge the
USPTO's Patent Term Adjustment (PTA) calculations in patents
where an RCE has been filed. For example, both Exelixis, Inc.
v. Kappos (Civ. Action No. 1:12-cv-00574-LMB-TCB) (E.D. Va.
May 25, 2012) and Human Genome Sciences, Inc. v. Kappos
(Civil Action No. 1:12-cv-00607-GBL-TCB) (E.D. Va. June 1, 2012)
raise the same issue regarding the USPTO's interpretation of 35
USC § 154(b)(1)(B)(i)). I think these challenges may have
merit, and patent holders facing similar PTA calculations may want
to consider pursuing similar civil actions against the USPTO.
Patent Term Adjustment
The PTA statute (35 USC § 154(b)) was created to
compensate for delays in the patent examination process that can
eat away at the effective term of the patent, now that patent term
is measured from the earliest U.S. priority date rather than the
patent grant date. The statute provides "guarantees"
against different types of USPTO delays, and